Search
N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
go.drugbank.com/drugs/DB08559Experimentalfrom the sulfur atom at position 1]. … These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870ExperimentalThe integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial
CDX-1135
go.drugbank.com/drugs/DB17607InvestigationalIt was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage. … CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalDeveloped by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalCreated by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).
Toyocamycin
go.drugbank.com/drugs/DB13916ExperimentalAntibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.
JLK-247
go.drugbank.com/drugs/DB17637ExperimentalJLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]
Surovatamig
go.drugbank.com/drugs/DB19420InvestigationalTNB-486 is under investigation in clinical trial NCT06564038 (A Study of AZD0486 Monotherapy or in Combination With Other Anti-cancer Agents for Mature B-cell Malignancies).
Edonerpic
go.drugbank.com/drugs/DB05938InvestigationalEdonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalThe use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.